When was ORGANOX acquired by LAUXERA?

ORGANOX was acquired by LAUXERA in 2023.

What was the revenue of ORGANOX at the time of the deal?

The revenue of ORGANOX at the time of the deal is estimated to be in the range of 10M - 30M GBP.

What was the EBITDA of ORGANOX during the acquisition?

ORGANOX's EBITDA is estimated to be in the range of 0M - 5M GBP.

How is the data for the ORGANOX acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the ORGANOX deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://lauxera.com/lauxera-capital-partners-has-led-a-25m-growth-investment-into-organox/

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaORGANOX

07/2023

LAUXERA invests in ORGANOX

UNITED KINGDOM Life Sciences / Medical Devices REV 10M - 30M GBP

Context

Lauxera Capital Partners has successfully led a £25 million growth investment into OrganOx, marking a pivotal minority platform entry into the high-barrier medical technology sector. Based in Oxford, England, the commercial-stage enterprise represents a strategic addition to the investor's specialized healthcare portfolio. The investment thesis centers on funding the global scale-up and commercial acceleration of an established, market-leading medical device platform. OrganOx leverages a proprietary technology, normothermic machine perfusion, which has already supported over 2,500 liver transplants worldwide. The strategic rationale of the capital injection is focused on rapidly expanding OrganOx's commercial footprint and deeply institutionalizing its partnerships with tier-one transplant centers across the United States and Europe.

ORGANOX, which reported an EBITDA margin of in 2023, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

OrganOx is a UK-based company founded in 2008, originating from the University of Oxford, which markets a groundbreaking device that can keep a liver graft functional outside the human body for up to 24 hours, significantly increasing the number of grafts eligible for transplantation. With innovative technology and a dedicated team, OrganOx has become a major player in the transplantation field, with a steadily growing revenue and established profitability, having generated a profit of £7.5 million in 2024. The company provides cutting-edge solutions to improve transplantation outcomes and meet the growing needs of patients. OrganOx is a success story in the medtech sector, with a history marked by strategic partnerships and targeted investments, such as the £25 million funding round led by Lauxera in 2023, and the $142 million funding round co-led by HealthQuest and Lauxera last February.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2023

2022

Other operations with ORGANOX

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2025	TERUMO	ORGANOX	UNITED KINGDOM	Medical Devices

REFERENCES

Revenue range: 10M - 30M GBP

EBITDA range: 0M - 5M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of ORGANOX by LAUXERA are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: organox

Acquirer: lauxera